<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="84988"><DrugName>mesenchymal stem cells (graft-versus-host disease), Cell2B</DrugName><DrugNamesKey><Name id="43008378">ImmuneSafe</Name></DrugNamesKey><DrugSynonyms><Name><Value>ImmuneSafe</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>mesenchymal stem cells (graft-versus-host disease), Cell2B</Value></Name></DrugSynonyms><CompanyOriginator id="1083023">Cell2B Advanced Therapeutics SA</CompanyOriginator><CompaniesSecondary><Company id="1083023">Cell2B Advanced Therapeutics SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1083023" type="Company"><TargetEntity id="5039710141" type="organizationId">Cell2B Advanced Therapeutics SA</TargetEntity></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"/><TargetEntity id="D018805" type="MeSH"/><TargetEntity id="-200243460" type="omicsDisease"/><TargetEntity id="953" type="siCondition"/></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"/><TargetEntity id="D015212" type="MeSH"/><TargetEntity id="-156308446" type="omicsDisease"/><TargetEntity id="394" type="siCondition"/></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"/><TargetEntity id="10028245" type="MEDDRA"/><TargetEntity id="D009103" type="MeSH"/><TargetEntity id="-1241225595" type="omicsDisease"/><TargetEntity id="112" type="siCondition"/></SourceEntity><SourceEntity id="3004" type="ciIndication"><TargetEntity id="10061890" type="MEDDRA"/><TargetEntity id="D016377" type="MeSH"/></SourceEntity><SourceEntity id="3395" type="ciIndication"><TargetEntity id="10000804" type="MEDDRA"/><TargetEntity id="D017114" type="MeSH"/></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"/><TargetEntity id="10018651" type="MEDDRA"/><TargetEntity id="D006086" type="MeSH"/><TargetEntity id="39812" type="ORPHANET"/><TargetEntity id="-1437372564" type="omicsDisease"/><TargetEntity id="1129" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="CU">Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="4">Advanced Therapy Medicinal Product</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="114">Sepsis</Indication><Indication id="189">Inflammatory bowel disease</Indication><Indication id="213">Multiple sclerosis</Indication><Indication id="3004">Organ transplantation</Indication><Indication id="3395">Acute liver failure</Indication><Indication id="616">Graft versus host disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="1596">Immunomodulator</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="864">Mesenchymal stem cell therapy</Technology><Technology id="857">Allogenic stem cell therapy</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2018-07-10T16:29:50.000Z</LastModificationDate><ChangeDateLast>2018-07-11T00:00:00.000Z</ChangeDateLast><AddedDate>2013-05-07T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1083023" linkType="Company"&gt;Cell2B&lt;/ulink&gt; was developing ImmuneSafe, a cell therapy consisting of allogeneic bone marrow derived mesenchymal stem cells expanded ex vivo in synthetic media, for the potential iv infusion treatment and prevention of immune and inflammatory diseases including graft-versus-host disease (GVHD) [&lt;ulink linkID="1416381" linkType="Reference"&gt;1416381&lt;/ulink&gt;], [&lt;ulink linkID="1615325" linkType="Reference"&gt;1615325&lt;/ulink&gt;]. In May 2013, the product was listed on the company's pipeline as being in pivotal clinical development for   GVHD. At that time, the therapy was  also listed as being in preclinical development for solid organ transplantation, inflammatory bowel disease, multiple sclerosis, acute liver failure, and fulminant sepsis [&lt;ulink linkID="1416381" linkType="Reference"&gt;1416381&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2014,  the EMA's COMP adopted a positive opinion recommending ImmuneSafe for Orphan drug designation for the prevention of GVHD [&lt;ulink linkID="1615325" linkType="Reference"&gt;1615325&lt;/ulink&gt;]; in December 2014, Orphan designation was granted [&lt;ulink linkID="1626707" linkType="Reference"&gt;1626707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, ImmuneSafe was granted advanced therapy medicinal product (ATMP) classification by the EMA [&lt;ulink linkID="1416418" linkType="Reference"&gt;1416418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, the EMA's COMP recommended granting the product Orphan status for the treatment of GVHD [&lt;ulink linkID="1411042" linkType="Reference"&gt;1411042&lt;/ulink&gt;]; in June 2013, Orphan status was granted [&lt;ulink linkID="1442730" linkType="Reference"&gt;1442730&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2013, the product was listed on the company's pipeline as being in pivotal clinical development for   GVHD [&lt;ulink linkID="1416381" linkType="Reference"&gt;1416381&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2013, ImmuneSafe was listed as being in preclinical development for solid organ transplantation, inflammatory bowel disease, multiple sclerosis, acute liver failure, and fulminant sepsis [&lt;ulink linkID="1416381" linkType="Reference"&gt;1416381&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2018-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate>2018-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate>2018-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3395">Acute liver failure</Indication><StatusDate>2018-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3004">Organ transplantation</Indication><StatusDate>2018-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2018-07-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate>2013-05-07T00:00:00.000Z</StatusDate><Source id="1416381" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3004">Organ transplantation</Indication><StatusDate>2013-05-07T00:00:00.000Z</StatusDate><Source id="1416381" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2013-05-07T00:00:00.000Z</StatusDate><Source id="1416381" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2013-05-07T00:00:00.000Z</StatusDate><Source id="1416381" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3395">Acute liver failure</Indication><StatusDate>2013-05-07T00:00:00.000Z</StatusDate><Source id="1416381" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1083023">Cell2B Advanced Therapeutics SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate>2013-05-07T00:00:00.000Z</StatusDate><Source id="1416381" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="4">Advanced Therapy Medicinal Product</RegulatoryDesignation><OwnerCompany id="1083023">Cell2B Advanced Therapeutics SA</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of patients with acute graft-versus-host disease grades III and IV resistant to first line treatment</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-12T00:00:00.000Z</MileStoneDate><Source id="1416418" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1083023">Cell2B Advanced Therapeutics SA</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Prevention of graft-versus-host disease</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-12-16T00:00:00.000Z</MileStoneDate><Source id="1626707" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1083023">Cell2B Advanced Therapeutics SA</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Prevention of graft-versus-host disease</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2014-11-13T00:00:00.000Z</MileStoneDate><Source id="1615325" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1083023">Cell2B Advanced Therapeutics SA</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of graft-versus-host disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-06-07T00:00:00.000Z</MileStoneDate><Source id="1626707" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1083023">Cell2B Advanced Therapeutics SA</OwnerCompany><Country id="EU">EU</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of graft-versus-host disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-04-17T00:00:00.000Z</MileStoneDate><Source id="1615325" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>